1. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial. (19th March 2019) Authors: Egle, Alexander; Melchardt, Thomas; Obrtlíková, Petra; Smolej, Lukáš; Kozák, Tomáš; Steurer, Michael; Andel, Johannes; Burgstaller, Sonja; Mikušková, Eva; Gercheva, Liana; Nösslinger, Thomas; Papajík, Tomáš; Ladická, Miriam; Girschikofsky, Michael; Hrubiško, Mikuláš; Jäger, Ulrich; Voskova, Danie... Journal: Cancer medicine Issue: Volume 8:Number 4(2019:Apr.) Page Start: 1401 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Issue 7 (July 2016) Authors: Greil, Richard; Obrtlíková, Petra; Smolej, Lukáš; Kozák, Tomáš; Steurer, Michael; Andel, Johannes; Burgstaller, Sonja; Mikušková, Eva; Gercheva, Liana; Nösslinger, Thomas; Papajík, Tomáš; Ladická, Miriam; Girschikofsky, Michael; Hrubiško, Mikuláš; Jäger, Ulrich; Fridrik, Michael; Pecherstorfer, M... Journal: Lancet Issue: Volume 3:Issue 7(2016) Page Start: e317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗